IMGN News and Press, ImmunoGen Inc. From 10/27/22

Summary ImmunoGen has a PDUFA on November 28. The NDA is based on data from the Soraya trial. The PFS data creates some doubt in investors. ImmunoGen ( IMGN ) has a tryst with the FDA on November 28, a priority review of its BLA for mirvetuximab soravtansine back...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 4, 2022 to discuss its third quarter 2022 operating results...

Mirvetuximab Plus Bevacizumab Demonstrated Meaningful Efficacy in Recurrent FRα-Positive Ovarian Cancer Across a Broad Range of FRα Expression Regardless of Prior Treatment; Data to be Highlighted in Oral Presentation Additional Clinical Benefit Outcomes from Piv...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, will participate in a fireside chat at the upcoming Guggenheim Nantucket Therapeutics Conf...

Patient-Reported Outcomes with Mirvetuximab Versus Chemotherapy in FORWARD I Study Reinforces Differentiated Tolerability Profile ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announc...

Clinical-stage biotech ImmunoGen ( NASDAQ: IMGN ) announced Wednesday that the company will share top-line data from its pivotal Phase 2 study for blood cancer drug pivekimab sunirine (pivekimab) in 2024 after regulatory feedback from a recent Type B meeting with the FDA. Th...

Review of Data from First 10 Patients Demonstrates Significant Activity and Favorable Tolerability in Both De Novo BPDCN Patients and Those with a P rior or Concomitant Hematologic Malignancy (PCHM) Following Discussion with FDA, CADENZA Patients to be Segm...

ImmunoGen announced that it will receive the FDA decision for mirvetuximab on November 28th. The deal with Oxford BioTechnologies will support further growth. ImmunoGen remains robust from a financial point of view. Two weeks ago, the leading biotech company ImmunoGen, I...

Shares of Sutro Biopharma have lost one-third of their value over the past 3 years. Consolidation in the antibody drug conjugate space has made it an attractive area for drug development. Sutro has inked a number of partnerships recently and management commentary leads me to belie...

Image source: The Motley Fool. ImmunoGen (NASDAQ: IMGN) Q2 2022 Earnings Call Jul 29, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: ImmunoGen (IMGN) Q2 2022 Earnings Call Transcript